SCHEDULE 13G/A: Avoro Capital Advisors and Behzad Aghazadeh Disclose 6.7% Passive Stake in Amicus Therapeutics

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have reported a 6.7% passive beneficial ownership stake in Amicus Therapeutics, Inc. as of March 31, 2025.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh (the "Reporting Persons") collectively hold 20,500,000 shares of Amicus Therapeutics, Inc. common stock.
• This represents a 6.7% beneficial ownership stake in the company.
• The ownership is primarily for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• The percentage is calculated based on 307,239,840 shares of Common Stock outstanding as of February 18, 2025.
• Both Reporting Persons have sole voting power and sole dispositive power over the 20,500,000 shares.
• This filing is an Amendment No. 4 to a Schedule 13G, indicating a routine update to a previously disclosed passive investment.

Sentiment

Score: 6

Explanation: The filing of a Schedule 13G by a reputable investment firm indicating a significant passive stake can be viewed as a positive signal of confidence in the company's long-term prospects, although it is a routine disclosure.

Positives

• A significant beneficial ownership stake (6.7%) by an investment advisory firm like Avoro Capital Advisors and its portfolio manager, Behzad Aghazadeh, can signal confidence in Amicus Therapeutics, Inc.
• The stated purpose of the acquisition is "solely for investment purposes," indicating a passive, long-term interest rather than an activist intent to influence control.

Risks

• No specific risks related to Amicus Therapeutics, Inc. are mentioned in this Schedule 13G filing, as it primarily concerns beneficial ownership disclosure.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure for institutional investors holding significant passive stakes in publicly traded companies, common across all industries, including biotechnology and pharmaceuticals where Amicus Therapeutics operates. It reflects an investment decision by a specialized life sciences fund.

Related Party Transactions

• Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock, indicating it is the ultimate beneficial owner for whom Avoro Capital Advisors LLC manages the investment.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor may provide a degree of confidence or validation regarding the company's value proposition.

Key Dates

Keywords

Amicus Therapeutics, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, beneficial ownership, common stock, investment, passive stake, biotechnology, pharmaceutical